Rapid Micro Biosystems Posts 11% Revenue Growth in Q1 2026, Boosted by Consumable Sales
Event summary
- Q1 2026 revenue grew 11% YoY to $8.0M, with product revenue up 36% and consumable revenue up over 30%.
- Placed 6 Growth Direct systems in Q1 2026, double the 3 systems placed in Q1 2025.
- Recurring revenue increased 28% YoY, comprising 63% of total revenue.
- Product gross margin improved by 15 percentage points, consumable gross margin by 33 percentage points.
- Reaffirmed full-year 2026 revenue guidance of $37M–$41M and gross margin guidance of ~20%.
The big picture
Rapid Micro Biosystems' Q1 2026 results reflect strong demand for its automation solutions in pharmaceutical manufacturing, particularly in consumables and recurring revenue streams. The strategic collaboration with MilliporeSigma underscores the company's push for enterprise-level deployments, aligning with broader industry trends toward QC automation and data integrity compliance. The reaffirmed full-year guidance suggests cautious optimism amid rising operating expenses and net losses.
What we're watching
- Recurring Revenue Growth
- Whether the 28% YoY increase in recurring revenue can sustain momentum, given its 63% share of total revenue.
- Gross Margin Expansion
- The pace at which product and consumable gross margins improve, following Q1's significant gains.
- System Placement Trends
- How the doubling of Growth Direct system placements impacts full-year guidance and long-term customer adoption.